MAPKAP1 and NRAS

Number of citations of the paper that reports this interaction (PubMedID 30639242)
7

Data Source:
BioGRID (imaging technique, affinity chromatography technology, pull down, far western blotting)

		MAPKAP1	NRAS
Description		MAPK associated protein 1	NRAS proto-oncogene, GTPase
Image
GO Annotations	Cellular Component	Nucleoplasm Cytoplasm Golgi Apparatus Cytosol Plasma Membrane Cytoplasmic Vesicle TORC2 Complex	Golgi Membrane Golgi Apparatus Plasma Membrane Membrane Extracellular Exosome Tertiary Granule Membrane
	Molecular Function	Protein Binding Phosphatidylinositol-4,5-bisphosphate Binding Phosphatidylinositol-3,4,5-trisphosphate Binding Ras GTPase Binding Protein Kinase Binding Phosphatidylinositol-3,4-bisphosphate Binding Phosphatidic Acid Binding Phosphatidylinositol-3,5-bisphosphate Binding	GTPase Activity Protein Binding GTP Binding GDP Binding Protein-containing Complex Binding
	Biological Process	Substantia Nigra Development Establishment Or Maintenance Of Actin Cytoskeleton Polarity Activation Of Protein Kinase B Activity Positive Regulation Of Peptidyl-serine Phosphorylation TORC2 Signaling Negative Regulation Of Ras Protein Signal Transduction Regulation Of Cellular Response To Oxidative Stress	MAPK Cascade Positive Regulation Of Endothelial Cell Proliferation Stimulatory C-type Lectin Receptor Signaling Pathway Ras Protein Signal Transduction Neutrophil Degranulation
Pathways		PIP3 activates AKT signaling CD28 dependent PI3K/Akt signaling VEGFR2 mediated vascular permeability Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants
Drugs
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Multiple myeloma Adrenal carcinoma Thyroid cancer Hepatocellular carcinoma Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS Malignant melanoma
GWAS		Body mass index ( 28892062) Diverticular disease ( 30177863) Itch intensity from mosquito bite ( 28199695) Itch intensity from mosquito bite adjusted by bite size ( 28199695) Medication use (calcium channel blockers) ( 31015401) Resting heart rate ( 27798624) Sleep duration ( 30531941) Smoking status (ever vs never smokers) ( 30643258)	Autism ( 24189344)
Interacting Genes		9 interacting genes: ABCB1 AKT1 CDC42EP1 ECI1 MAPK8 NRAS PRKCA SGK1 YWHAG	25 interacting genes: ACVR1 ARHGAP4 BCL2 DNAJB1 EEF1A1 HRAS LZTR1 MAPKAP1 MTOR PIK3CA PIK3CG PLCE1 RACGAP1 RAF1 RAP1GDS1 RASGRP2 RASSF5 RGL2 RPS20 SHOC2 SMAD4 SMURF2 SRI UBE2L3 WDR76
Entrez ID		79109	4893
HPRD ID		17464	01273
Ensembl ID		ENSG00000119487	ENSG00000213281
Uniprot IDs		A0A024R863 Q9BPZ7	P01111 Q5U091
PDB IDs		3VOQ 5ZCS	2N9C 3CON 5UHV 6E6H
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?